Cetuximab ‘No Survival Advantage’ for Advanced Biliary-Tract Cancer

Cetuximab fails to improve the outcome of patients with advanced biliary-tract cancer given first-line chemotherapy. 

ESMO members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.